Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EOLS
- Price
- 9.54
- Stock movement up
- +0.13 (1.33%)
- Company name
- Evolus Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 604.09M
- Ent value
- 742.77M
- Price/Sales
- 2.43
- Price/Book
- 102.56
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 151.43
- PEG
- -
- EPS growth
- -10.81%
- 1 year return
- -25.29%
- 3 year return
- -6.44%
- 5 year return
- 22.00%
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
EOLS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.43 |
| Price to Book | 102.56 |
| EV to Sales | 2.99 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 63.32M |
| EPS (TTM) | -0.88 |
| FCF per share (TTM) | -0.40 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 248.33M |
| Gross profit (TTM) | 169.48M |
| Operating income (TTM) | -34.00M |
| Net income (TTM) | -55.46M |
| EPS (TTM) | -0.88 |
| EPS (1y forward) | 0.06 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 68.25% |
| Operating margin (TTM) | -13.69% |
| Profit margin (TTM) | -22.33% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 85.03M |
| Net receivables | 44.64M |
| Total current assets | 150.36M |
| Goodwill | 21.21M |
| Intangible assets | 46.59M |
| Property, plant and equipment | 0.00 |
| Total assets | 229.61M |
| Accounts payable | 13.84M |
| Short/Current long term debt | 8.67M |
| Total current liabilities | 60.81M |
| Total liabilities | 223.72M |
| Shareholder's equity | 5.89M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -21.99M |
| Capital expenditures (TTM) | 3.43M |
| Free cash flow (TTM) | -25.42M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -941.60% |
| Return on Assets | -24.15% |
| Return on Invested Capital | -740.36% |
| Cash Return on Invested Capital | -339.38% |
Evolus, Inc. (NASDAQ:EOLS) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsNareg Sagherian - VP and Head of Global IR and...
November 7, 2024
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 9.45 |
| Daily high | 9.94 |
| Daily low | 9.06 |
| Daily Volume | 1.12M |
| All-time high | 38.49 |
| 1y analyst estimate | 23.43 |
| Beta | 1.31 |
| EPS (TTM) | -0.88 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 May 2025 |
Downside potential
Loading...
Downside potential data
| EOLS | S&P500 | |
| Current price drop from All-time high | -75.21% | -12.89% |
| Highest price drop | -92.41% | -56.47% |
| Date of highest drop | 29 Oct 2020 | 9 Mar 2009 |
| Avg drop from high | -67.61% | -11.07% |
| Avg time to new high | 95 days | 12 days |
| Max time to new high | 1723 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
604.09M
Marketcap category
Small-cap
Description
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Employees
322
Website
Investor relations
-
SEC filings
CEO
David Moatazedi
Country
USA
City
Newport Beach
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page